Showing 26–50 of 200 documents
Sorted by hybrid relevance (keyword + semantic via RRF)
Wenhong Zhang, PhD,MD
…or MDR-TB treatment success rates suggest that current drug regimens are suboptimal. In addition, they are costly with a high pill burden, as many drugs, with significant potential for adverse events, are given for a long duration. These factors also inhibit good treatment compli…
Kelly Dooley, MD, Daniel W Fitzgerald, MD, Ekaterina V Kurbatova, MD, PhD, MPH, Wendy Carr, PhD
…se of this study is to determine whether one or two 17-week regimens of tuberculosis treatment bedaquiline (B or BDQ), moxifloxacin (M), pyrazinamide (Z)-- (BMZ) plus either Rifabutin (Rb) or Delamanid (D or DLM) are as effective as a standard six-month regimen for treatment of p…
Kavitha Saravu, Madhukar Pai
…drugs (e.g. bedaquiline) as well as shorter, individualized regimens, based on DST results.[2] In a study published in this issue of Lung India, Singh et al. reported on the treatment outcomes of a modified DOTS-plus strategy among 98 consecutive culture-proven adult MDR-TB patie…
Jann-Yuan Wang, MD, PhD
…1.00-1.02\], p = 0.218). The 3HP regimen is among the four regimens for LTBI that is recommended by the WHO and is also probably the most promising regimen because of its convenience, with only 12 doses requried. With its effectiveness well established, the major remaining conce…
Lindsay McKenna, Jennifer Furin
… needed on the safety and efficacy of pretomanid-containing regimens, and such data can be found in the paper published in The Lancet Respiratory Medicine by Conor Tweed and colleagues.6Tweed CD Dawson R Burger DA et al.Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide duri…
First Affiliated Hospital of Zhejiang University
…o determine whether the sitafloxacin-containing three-month regimens are as effective as the standard six-month regimen and the four-month rifapentine and moxifloxacin regimen (substitution of rifapentine for rifampin and moxifloxacin for ethambutol) for treatment of pulmonary tu…
Shanghai Pulmonary Hospital, Shanghai, China
…ity (EBA), safety, and tolerability of 4-month short-course regimens containing bedaquiline, moxifloxacin, and pyrazinamide in patients with drug-susceptible tuberculosis. This is a prospective, randomized, controlled, multicenter study planned to enroll 45 rifampicin-susceptible…
Kwonjune J. Seung, Cathy Hewison
…rug-resistant tuberculosis to more effective and safer drug regimens that avoid debilitating side-effects, such as permanent hearing loss.2Farmer PE Better and safer treatment for multidrug-resistant tuberculosis.Lancet. 2018; 392: 798-800Summary Full Text Full Text PDF PubMed Sc…
Tari Nur Fauziyantini, Umi Yuniarni, Lanny Mulqie
…since 2023, Indonesia has implemented several TB-RO therapy regimens, namely BPaLM (6 months), BPaL (6 months), 9 month regimen, and long-term regimen (18-24 months). The choice of regimen is based on the patient's condition, treatment history, and level of resistance to certain …
N.А. Lytvynenko, Y. I. Feschenko, Maryna Pogrebna, A.S. Lapheta, L.V. Shcherbakova, et al.
…iveness of various shortened standard or modified treatment regimens for patients with multidrugresistant tuberculosis. Materials and methods. A prospective observational study was carried out to study different shortened AMBT regimens for 346 patients with multidrug-resistant t…
Malik Zohaib Ali, Taru S. Dutt, Amy L. MacNeill, Amanda Walz, Camron Pearce, et al.
…ltaneously avoiding the L-associated AEs. The BPaL and BPaS regimens were compared in the BALB/c and C3HeB/FeJ murine chronic TB efficacy models. After 4-weeks of treatment, both regimens promoted equivalent bactericidal effect in both TB murine models. However, treatment with BP…
Innocent Murhula Kashongwe, Leopoldine Mbulula, Fina Mawete, Nicole Anshambi, Nadine Maingowa, et al.
…w approach improved favorable outcomes. Both short and long regimens reached a high level of favorable outcome compared to the previous study. The short regimen, well supervised seems to be superior to the long regimen in term of Death rate and loss to follow up (LTFU).
Bavesh D Kana
…ltaneously avoiding the L-associated AEs. The BPaL and BPaS regimens were compared in the BALB/c and C3HeB/FeJ murine chronic TB efficacy models. After 4-weeks of treatment, both regimens promoted equivalent bactericidal effect in both TB murine models. However, treatment with BP…
Malik Zohaib Ali, Taru S Dutt, Amy MacNeill, Amanda Walz, Camron Pearce, et al.
…ltaneously avoiding the L-associated AEs. The BPaL and BPaS regimens were compared in the BALB/c and C3HeB/FeJ murine chronic TB efficacy models. After 4-weeks of treatment, both regimens promoted equivalent bactericidal effect in both TB murine models. However, treatment with BP…
Malik Zohaib Ali, Taru S Dutt, Amy MacNeill, Amanda Walz, Camron Pearce, et al.
…ltaneously avoiding the L-associated AEs. The BPaL and BPaS regimens were compared in the BALB/c and C3HeB/FeJ murine chronic TB efficacy models. After 4-weeks of treatment, both regimens promoted equivalent bactericidal effect in both TB murine models. However, treatment with BP…
Malik Zohaib Ali, Taru S Dutt, Amy MacNeill, Amanda Walz, Camron Pearce, et al.
…ltaneously avoiding the L-associated AEs. The BPaL and BPaS regimens were compared in the BALB/c and C3HeB/FeJ murine chronic TB efficacy models. After 4-weeks of treatment, both regimens promoted equivalent bactericidal effect in both TB murine models. However, treatment with BP…
Masayuki Ikeda, Hiroki Matsui, Yasuhiro Morimoto, Norihiko Kubota, Tatsuya Nagai, et al.
…%) patients received clarithromycin- and azithromycin-based regimens, respectively. The aORs for initial regimen modification were as follows; age 1.05 (95% CI; 1.01-1.10), women 0.77 (95% CI; 0.34-1.74), body mass index 1.06 (95% CI; 0.96-1.18), smear-positive status 0.85 (95% C…
R. Swapna, Karanth M P Swathi, M. Somashekar, Asit Kumar Chakraborty, J.S. Akshata, et al.
…entional longer regimen. Evaluating the performance of both regimens in a programmatic setting will help in tailoring the treatment regimen of MDR-TB. Objectives: To estimate the duration of sputum smear conversion in the shorter MDR-TB regimen. 2. To compare the treatment outcom…
Narendran Gopalan, DNB (Chest), Soumya Swaminathan, MD
…dividuals treated for TB treated with standard intermittent regimens. The study would generate data on the efficacy of daily and thrice weekly regimen of ATT in pulmonary TB patients with HIV in the presence of highly active antiretroviral therapy (HAART). Not many trials have co…
Hisayuki Shuto, Kosaku Komiya, Akihiko Goto, Takamasa Kan, Kokoro Honjo, et al.
…ficacy and safety of fluoroquinolone-containing combination regimens as an alternative remain uncertain. This study aimed to compare the efficacy and safety of fluoroquinolone-containing regimens with those of the standard regimens for treating pulmonary MAC disease. METHODS: We …
Taipei Medical University WanFang Hospital
… (Ri-TB) and TB patients for whom rifamycin-sparing anti-TB regimens are preferred due to drug-drug interaction (Rs-TB). Trial intervention The novel regimen will be given in two phases: 1. An intensive phase consisting of isoniazid, bedaquiline, moxifloxacin and pyrazinamide …
Lyndon P. James, Fayette Klaassen, Sedona Sweeney, Jennifer Furin, Molly F. Franke, et al.
…ging evidence suggests that shortened, simplified treatment regimens for rifampicin-resistant tuberculosis (RR-TB) can achieve comparable end-of-treatment outcomes to longer regimens. We compared a 6-month regimen containing bedaquiline, pretomanid, linezolid, and moxifloxacin (B…
Xueyi Chen, Carlos E Ruiz-Gonzalez, Yuderleys Masias-Leon, Mantej Singh, Oscar J Nino-Meza, et al.
…ains unexplored.Figure 1.Evaluation of rifamycin-containing regimens in the mouse model of TB meningitis.(A) Mice were infected intraventricularly via Burr hole using a syringe and stereotaxic instrument, treatment were initiated two weeks after (designated as day 0) and continue…
Malik Zohaib Ali, Taru S. Dutt, Amy L. MacNeill, Amanda Walz, Johnathan Patterson, et al.
…ltaneously avoiding the L-associated AEs. The BPaL and BPaS regimens were compared in the Balb/c and C3HeB/FeJ murine chronic TB efficacy models. After 4-weeks of treatment, both regimens promoted equivalent bactericidal effect in both TB murine models. However, treatment with BP…
Malik Zohaib Ali, Taru S. Dutt, Amy L. MacNeill, Amanda Walz, Johnathan Patterson, et al.
…ltaneously avoiding the L-associated AEs. The BPaL and BPaS regimens were compared in the Balb/c and C3HeB/FeJ murine chronic TB efficacy models. After 4-weeks of treatment, both regimens promoted equivalent bactericidal effect in both TB murine models. However, treatment with BP…